Skip to content
DataLookout
Menu

NCT06659068

Efficacy of Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regulator Cells, IL17/IL-10 Ratio, and Disease Activity in Systemic Lupus Erythematosus Patients

StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

CD4+CD25+Foxp3+ regulatory T cells,
Timeframe: From enrollment to the end of the treatment at 12 weeks
IL-17/IL-10 ratio
Timeframe: From enrollment to the end of the treatment at 12 weeks
SLEDAI-2K score
Timeframe: From enrollment to the end of the treatment at 12 weeks

Arms and interventions

Seluang fish oil (Rasbora argyrotaenia) and SynbioticExperimental

Seluang fish oil (Rasbora argyrotaenia) and Synbiotic The patients were given a capsule containing seluang fish oil (Rasbora argyrotaenia) once a day and also synbiotic once a day

PlaceboPlacebo comparator

Placebo The patients were given placebo capsules of seluang fish oil (Rasbora argyrotaenia) and synbiotics once a day

Dietary supplements: Seluang fish oil (Rasbora argyrotaenia) and synbiotic, Placebo

Sites

1 site in 1 country

  • Mohammad Hoesin General HospitalPalembang, South Sumatera, Indonesia